Back to Our Science

Cell Therapy Delivery Systems


EXUMA’s proprietary, centralized CCT3 CAR-T process is launch-ready and needs no further modifications to be commercially viable.

  • A proprietary process which could support market entry
  • 12-day vein-to-vein, fully closed, fresh in, frozen out process
  • No manufacturing failures from IIT studies in China
  • Uses real-time monitoring electronic batch record bar code system to help mitigate potential errors


Rapid Point-of-Care (rPOC) subcu (SC) could greatly expand access to a potentially life-saving CAR-T therapy while reducing costs by avoiding the need for adjuvant chemotherapy and shortening the hospital stay.

  • A revolutionary process which could dramatically change the CAR-T landscape
  • Subcutaneously injected CAR-T product never leaves the patient’s side and can be manufactured in less than six hrs
  • Decreased complexity has potential for reduced cost and increases access
  • Leverages existing oncology infusion clinic infrastructure